Cargando…

Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway

Alzheimer’s disease (AD) is a slowly progressive form of dementia, characterized by memory impairment and cognitive dysfunction. AD is mainly characterized by the deposition of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain, along with neuronal degeneration and high le...

Descripción completa

Detalles Bibliográficos
Autores principales: Oguchi, Tatsunori, Ono, Ran, Tsuji, Mayumi, Shozawa, Hidenobu, Somei, Masayuki, Inagaki, Manami, Mori, Yukiko, Yasumoto, Taro, Ono, Kenjiro, Kiuchi, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651005/
https://www.ncbi.nlm.nih.gov/pubmed/29089887
http://dx.doi.org/10.3389/fnagi.2017.00337
_version_ 1783272808170651648
author Oguchi, Tatsunori
Ono, Ran
Tsuji, Mayumi
Shozawa, Hidenobu
Somei, Masayuki
Inagaki, Manami
Mori, Yukiko
Yasumoto, Taro
Ono, Kenjiro
Kiuchi, Yuji
author_facet Oguchi, Tatsunori
Ono, Ran
Tsuji, Mayumi
Shozawa, Hidenobu
Somei, Masayuki
Inagaki, Manami
Mori, Yukiko
Yasumoto, Taro
Ono, Kenjiro
Kiuchi, Yuji
author_sort Oguchi, Tatsunori
collection PubMed
description Alzheimer’s disease (AD) is a slowly progressive form of dementia, characterized by memory impairment and cognitive dysfunction. AD is mainly characterized by the deposition of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain, along with neuronal degeneration and high levels of oxidative stress. Cilostazol (CSZ) was recently found to suppress the progression of cognitive decline in patients with stable AD receiving acetylcholinesterase inhibitors. This present study aimed to clarify the mechanism by which CSZ protects neurons from degeneration associated with Aβ(1–42). We used Aβ(1–42) to induce neurotoxicity in human neuroblastoma SH-SY5Y cells. Cells were pretreated with CSZ before co-treatment with Aβ. To evaluate the effect of CSZ on oxidative stress, we examined levels of reactive oxygen species (ROS), nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity, mRNA expression of NOX4, and Cu/Zn-Superoxide Dismutase (SOD), as well as apoptosis biomarkers [MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), caspase-3 and -9 activities and staining of annexin V]. We also assayed the activity of mitogen-activated protein kinases (MAPK): p38 MAPK and extracellular signal-regulated kinase1/2 (ERK1/2), and biomarkers of mitochondrial function (Bcl-2 and Bax), and cyclic adenosine monophosphate response element-binding protein (CREB). Aβ-induced oxidative stress (ROS, NOX4 activity, and expression of NOX mRNA), caspase activation (caspase-3 and -9), and p38 MAPK phosphorylation were suppressed by co-treatment with CSZ, but not by ERK1/2 activation. In addition, pretreatment with CSZ suppressed Aβ-induced apoptosis and increased cell viability via suppression of Bax (a proapoptotic protein), upregulation of Bcl-2 (an antiapoptotic protein) and Cu/Zn-SOD (a superoxide scavenging enzyme), and phosphorylation of CREB. These findings suggested that CSZ could counteract neurotoxicity through multiple mechanisms, one mechanism involving the attenuation of oxidative stress by suppressing NOX activity and Nox mRNA expression in Aβ-induced neurotoxicity and another involving the anti-neurotoxic effect via the ERK1/2/phosphorylated CREB pathway.
format Online
Article
Text
id pubmed-5651005
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56510052017-10-31 Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway Oguchi, Tatsunori Ono, Ran Tsuji, Mayumi Shozawa, Hidenobu Somei, Masayuki Inagaki, Manami Mori, Yukiko Yasumoto, Taro Ono, Kenjiro Kiuchi, Yuji Front Aging Neurosci Neuroscience Alzheimer’s disease (AD) is a slowly progressive form of dementia, characterized by memory impairment and cognitive dysfunction. AD is mainly characterized by the deposition of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain, along with neuronal degeneration and high levels of oxidative stress. Cilostazol (CSZ) was recently found to suppress the progression of cognitive decline in patients with stable AD receiving acetylcholinesterase inhibitors. This present study aimed to clarify the mechanism by which CSZ protects neurons from degeneration associated with Aβ(1–42). We used Aβ(1–42) to induce neurotoxicity in human neuroblastoma SH-SY5Y cells. Cells were pretreated with CSZ before co-treatment with Aβ. To evaluate the effect of CSZ on oxidative stress, we examined levels of reactive oxygen species (ROS), nicotinamide adenine dinucleotide phosphate oxidase (Nox) activity, mRNA expression of NOX4, and Cu/Zn-Superoxide Dismutase (SOD), as well as apoptosis biomarkers [MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), caspase-3 and -9 activities and staining of annexin V]. We also assayed the activity of mitogen-activated protein kinases (MAPK): p38 MAPK and extracellular signal-regulated kinase1/2 (ERK1/2), and biomarkers of mitochondrial function (Bcl-2 and Bax), and cyclic adenosine monophosphate response element-binding protein (CREB). Aβ-induced oxidative stress (ROS, NOX4 activity, and expression of NOX mRNA), caspase activation (caspase-3 and -9), and p38 MAPK phosphorylation were suppressed by co-treatment with CSZ, but not by ERK1/2 activation. In addition, pretreatment with CSZ suppressed Aβ-induced apoptosis and increased cell viability via suppression of Bax (a proapoptotic protein), upregulation of Bcl-2 (an antiapoptotic protein) and Cu/Zn-SOD (a superoxide scavenging enzyme), and phosphorylation of CREB. These findings suggested that CSZ could counteract neurotoxicity through multiple mechanisms, one mechanism involving the attenuation of oxidative stress by suppressing NOX activity and Nox mRNA expression in Aβ-induced neurotoxicity and another involving the anti-neurotoxic effect via the ERK1/2/phosphorylated CREB pathway. Frontiers Media S.A. 2017-10-17 /pmc/articles/PMC5651005/ /pubmed/29089887 http://dx.doi.org/10.3389/fnagi.2017.00337 Text en Copyright © 2017 Oguchi, Ono, Tsuji, Shozawa, Somei, Inagaki, Mori, Yasumoto, Ono and Kiuchi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Oguchi, Tatsunori
Ono, Ran
Tsuji, Mayumi
Shozawa, Hidenobu
Somei, Masayuki
Inagaki, Manami
Mori, Yukiko
Yasumoto, Taro
Ono, Kenjiro
Kiuchi, Yuji
Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title_full Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title_fullStr Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title_full_unstemmed Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title_short Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
title_sort cilostazol suppresses aβ-induced neurotoxicity in sh-sy5y cells through inhibition of oxidative stress and mapk signaling pathway
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651005/
https://www.ncbi.nlm.nih.gov/pubmed/29089887
http://dx.doi.org/10.3389/fnagi.2017.00337
work_keys_str_mv AT oguchitatsunori cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT onoran cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT tsujimayumi cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT shozawahidenobu cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT someimasayuki cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT inagakimanami cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT moriyukiko cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT yasumototaro cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT onokenjiro cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway
AT kiuchiyuji cilostazolsuppressesabinducedneurotoxicityinshsy5ycellsthroughinhibitionofoxidativestressandmapksignalingpathway